Nautilus validated its next‑generation EcoCore cooling unit for Vera Rubin‑class AI GPU clusters, proving it can safely and efficiently handle 4 MW‑plus high‑density workloads that legacy systems struggle to support.

At Pangaea Ventures, we invest in bold hard tech innovations reshaping the future of industry and solving our planet’s (and its people’s) most pressing challenges. Kanvas Biosciences is a quintessential example leveraging groundbreaking spatial biology technology and precision microbiome therapeutics to address untapped opportunities in medicine and beyond. Here’s why we’ve invested again.

Co-led by DCVC and Lions Capital with participation from the Gates Foundation, ATHOS, Germin8, Ki Tua Fund, Pangaea Ventures and others, the round will fund clinical trials for Kanvas’ lead drug candidates and more.

With decades of experience scaling industrial businesses, Kravtsov will focus on expanding CarbonCure’s CO₂ utilization technology across more producers and regions.

The funding will accelerate commercialization and global deployment of pH7’s closed-loop platform, enabling economic recovery of critical minerals from low-grade ores, tailings, and complex feedstocks that were previously uneconomic to process.

Aspect Biosystems has announced a $280M partnership with Government of Canada to accelerate development of its bioengineered cellular medicines for serious metabolic and endocrine diseases.

pH7 Technologies is expanding its Vancouver facility to boost North American recovery of critical platinum group metals from recycled materials, while cutting wastewater, energy use, and carbon footprint relative to conventional refining.

Kanvas Biosciences has received the green light to begin enrolling and treating patients in a Phase 1 clinical trial of KAN-004, a live biotherapeutic designed to treat immune checkpoint inhibitor–induced colitis

InSolare Energy and Versogen have entered a technology transfer and strategic collaboration to jointly develop and commercialize advanced AEM electrolyzer stacks for India’s green hydrogen market.

Kanvas Biosciences has welcomed Dr. Stephen Quake to its Board of Directors, adding one of the world’s leading bioengineers to an already strong team.

The honor validates Tidal Vision’s thesis that biosolutions win at scale only when they outcompete on performance, economics, and ease of use, and highlights the team’s progress bringing chitosan‑based chemistry into water treatment, agriculture, and materials applications.

TS601 builds on NewLeaf’s PPFM platform and induced systemic resistance mode of action, giving growers a new biological tool to protect yield while supporting more sustainable production.

We’re proud to see pH7 Technologies named a finalist in Wheaton Precious Metals’ 2025/2026 Future of Mining Challenge, recognizing solutions that can reshape how the industry sources critical metals.

By replacing abrasive slurries with a chemically reactive pad and polishing fluid, Chakra is designed to improve yield, reduce water and waste, and help enable advanced AI chips, HBM, and cutting‑edge packaging flows.

Nautilus Data Technologies sits on the bleeding edge of one of the most important shifts in digital infrastructure: how we cool ever more powerful data centers without overwhelming local water and energy systems. Their EcoCore platform is a modular, facility‑scale liquid cooling solution designed to make AI‑ready data centers more efficient, flexible, and sustainable wherever they are built.

Read on to learn in detail why we were proud to lead Nautilus’ recently closed Series B.

Nautilus Data Technologies has announced the close of a Series B round, led by Pangaea Ventures, to accelerate the global expansion of its facility-scale liquid cooling platform for data centers.

Aspect Biosystems and Novo Nordisk have just announced they are deepening their collaboration to accelerate advanced cellular medicines that aim to deliver functional cures for diabetes.

Membrion has been named to Cleantech Group’s 2026 Global Cleantech 100, a list recognizing private companies poised to deliver significant environmental and infrastructure impact in the coming decade.

Pangaea Ventures is proud to double down with Ardent, joining their just-announced Series B. Ardent’s exceptional membrane chemistry is built to solve what others can’t. With real-world deployments scaling and a committed, visionary team at the helm, Ardent stands poised to redefine the future of industrial separations across chemicals, energy, and broader heavy industry.

Ardent has annouced the first close of its Series B co-led by Pangaea Ventures and Xplor Ventures, with participation from Syensqo Ventures and Chevron Technology Ventures.